title: Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis.
abstract: BACKGROUND
  Dexlansoprazole MR heals all grades of erosive oesophagitis (EO).
  
  
  OBJECTIVE
  To assess efficacy and safety of dexlansoprazole MR in maintaining healed EO and heartburn relief.
  
  
  METHODS
  In this randomized, double-blind trial, 445 patients with healed EO received dexlansoprazole MR 30 mg or 60 mg or placebo once daily for 6 months. This trial assessed maintenance of endoscopic healing (primary endpoint) and continued symptom relief based on daily diaries (secondary endpoints).
  
  
  RESULTS
  Dexlansoprazole MR 30 mg and 60 mg were superior to placebo for maintaining healed EO (P < 0.0025; Hochberg's). By life-table analysis, maintenance rates were 75%, 83% and 27% for dexlansoprazole MR 30 mg, 60 mg and placebo respectively. Crude maintenance rates were 66% for both dexlansoprazole MR doses and 14% for placebo. Dexlansoprazole MR controlled heartburn (medians of 91-96% for 24-h heartburn-free days, 96-99% for heartburn-free nights). The only more common adverse event occurring at a significantly higher rate in dexlansoprazole MR groups than placebo when analysed per patient-months of exposure was upper respiratory tract infection.
  
  
  CONCLUSIONS
  Dexlansoprazole MR effectively maintained EO healing and symptom relief; most patients were heartburn-free for >90% of days. Both doses were well tolerated.
authors.affiliation: University of Pennsylvania School of Medicine, Division of Gastroenterology, Philadelphia, PA, USA.
authors.forename: D C
authors.initials: DC
authors.lastname: Metz
authors.forename: C W
authors.initials: CW
authors.lastname: Howden
authors.forename: M C
authors.initials: MC
authors.lastname: Perez
authors.forename: L
authors.initials: L
authors.lastname: Larsen
authors.forename: J
authors.initials: J
authors.lastname: O'Neil
authors.forename: S N
authors.initials: SN
authors.lastname: Atkinson
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D003692:Delayed-Action Preparations / Q000627:therapeutic use; D064748:Dexlansoprazole; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004941:Esophagitis / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects*; D006356:Heartburn / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D054328:Proton Pump Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011788:Quality of Life; D055502:Secondary Prevention; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D003692:Delayed-Action Preparations; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D064748:Dexlansoprazole